For how we live.
In TroFuse-005, 776 people with advanced endometrial cancer treated previously with chemotherapy and immunotherapy were randomised to sac-TMT or chemotherapy. Median overall survival was 19.0 versus 12.1 months.
In KEYNOTE-C93, 299 people with mismatch repair-deficient advanced endometrial cancer were randomised to pembrolizumab or to carboplatin plus paclitaxel. Median progression-free survival was 38.2 versus 8.4 months.
Five-year follow-up of a Chinese randomised trial shows paclitaxel–cisplatin–capecitabine before chemoradiotherapy lifted failure-free survival from 63% to 78% in high-risk disease — at the cost of more toxicity.
In the phase 3 DRAGON-01 trial, delivering paclitaxel directly into the abdominal cavity on top of standard chemotherapy raised median survival to 19.4 months from 13.9 in gastric cancer with peritoneal spread.